Subsequently, using the p21 inhibitor (UC2288), we evaluated whether targeting the p53 pathway or CDKs alters the mRNA expression of CDK2 (Fig. 10a-c) and the cyclin A/CDK2 and P-p21 protein expression in FLT3-ITD AML (Fig. 10d-f, Fig. S5). This evidence concerns the gene CDKN1A and acute myeloid leukemia.